Search the Newsreel

¿Puede Abbott Laboratories (ABT) Estar 8% Infravalorada Tras Mejorar Su Previsión Anual?

Abbott Laboratories (ABT) schedules NYSE sale of stock from vested awards

Abbott Laboratories (ABT) has filed a Form 144 indicating a planned sale of 5,850 common shares through UBS Financial Services on or after August 11, 2026, on the NYSE. The shares originate from vested restricted stock awards granted on February 27, 2026, totaling 1,960, …

Abbott Partners With Google Health For AI-Powered Glucose Monitoring

Abbott has partnered with Google Health to integrate its Lingo continuous glucose monitor (CGM) data into the Google Health app, offering AI-driven recommendations for non-diabetic users. This collaboration aims to help users make better lifestyle choices and will involve a large-scale metabolic health study. …

Abbott to integrate Google’s AI health coach into wearable glucose monitoring tech

Abbott is partnering with Google to integrate Google's AI health coach into its Lingo wearable glucose monitoring technology. This collaboration aims to enhance the functionality of Abbott's continuous glucose monitoring system by providing users with AI-powered personalized health insights and coaching. The initiative was …

Why is Abbott Laboratories stock gaining today?

Abbott Laboratories stock rose 1.2% after announcing a multi-year collaboration with Google Health. This partnership will integrate glucose data from Abbott's Lingo biowearable continuous glucose monitor into the Google Health app, offering personalized health recommendations. The deal also includes a large-scale metabolic health study, …

Abbott and Google launch first-of-its-kind partnership to transform everyday health through glucose insights and AI

Abbott and Google Health have announced a multi-year partnership to integrate glucose insights from Abbott's Lingo biowearable with Google's AI and consumer technology. This collaboration aims to provide personalized metabolic insights through the Google Health app, helping users understand how daily behaviors affect their …

Abbott, Google to Study How Sleep and Activity Affect Glucose

Abbott has announced a multi-year partnership with Google Health to integrate insights from Abbott's Lingo continuous glucose monitor with Google's AI and consumer technology. This collaboration aims to provide personalized metabolic insights through the Google Health app, offering AI-powered guidance on nutrition, activity, sleep, …

Abbott Laboratories price shows more positive signals - Forecast today - 11-08-2026

Abbott Laboratories (ABT) is showing positive signals, with its stock trading above its 50-day Simple Moving Average and momentum indicators generating bullish signals. The outlook remains bullish as long as support at $102.90 holds, with a target resistance level at $114.00. This forecast suggests …

Handelsbanken Fonder AB Sells 444,592 Shares of Abbott Laboratories $ABT

Handelsbanken Fonder AB reduced its stake in Abbott Laboratories by 37.6% in the second quarter, selling 444,592 shares and retaining 736,804 shares valued at approximately $66.9 million. Abbott Laboratories reported strong quarterly results, exceeding analyst expectations with $12.59 billion in revenue and adjusted earnings …

Abbott Laboratories (ABT) Just Gave Investors Something To Think About

Abbott Laboratories (ABT) recently exceeded quarterly estimates and increased its annual profit forecast, driven by strong performance in cancer diagnostics and medical devices. The company's stock has shown a significant short-term rebound, up 28.77% over 90 days, despite being down over the past year. …

Abbott vs. Medtronic: Is Consistent Growth Better Than a Turnaround Story?

Abbott Laboratories (NYSE:ABT) and Medtronic (NYSE:MDT) are both prominent names in the Medtech space. Abbott Laboratories (NYSE:ABT) delivered strong fiscal Q2 2026 results, beating quarterly estimates and raising its annual profit forecast as robust demand for its cancer diagnostics and medical devices businesses helped …

Abbott Continues to Oppose Spinal Cord Stimulator Lawsuit MDL, Despite Mounting Claims

Abbott Laboratories is opposing the consolidation of spinal cord stimulator lawsuits into a multidistrict litigation (MDL), despite a growing number of claims alleging dangerous defects in its devices. While a similar MDL has already been established for Boston Scientific, Abbott argues that its cases …

Fluent Financial LLC Makes New $1.73 Million Investment in Abbott Laboratories $ABT

Vertrix Wealth Management LLC Invests $2.67 Million in Abbott Laboratories $ABT

Vertrix Wealth Management LLC initiated a new position in Abbott Laboratories (NYSE:ABT) during the second quarter, purchasing 29,377 shares valued at approximately $2.67 million. Institutional investors collectively own about 75.18% of the company. Abbott Laboratories reported strong quarterly earnings and revenue, beating estimates, and …

Abbott Laboratories (ABT) Stock Analysis: Exploring a 9.84% Potential Upside Amid Strong Revenue Growth

Gradient Investments LLC Sells 126,411 Shares of Abbott Laboratories $ABT

Gradient Investments LLC reduced its stake in Abbott Laboratories (ABT) by 34.9% in Q2 2026, selling over 126,000 shares but still retaining a significant holding worth $21.4 million. Despite this sale, institutional investors collectively own 75.18% of ABT. The company recently exceeded quarterly earnings …

Abbott Laboratories (ABT) Could Be 10% Undervalued On Its $1.35b Buyback Update

Abbott Laboratories (ABT) has completed a $1.35 billion share buyback, repurchasing over 14 million shares. Despite recent short-term gains, the company's shares are considered 9.5% undervalued, with a fair value estimated at $119.13 compared to its current price of $107.81. Growth drivers include expanding …

Avior Wealth Management LLC Lowers Stake in Abbott Laboratories $ABT

Avior Wealth Management LLC reduced its stake in Abbott Laboratories (NYSE:ABT) by 47.5% in the second quarter, selling 19,199 shares and retaining 21,257 shares valued at $1.93 million. Despite this, analysts maintain a "Moderate Buy" rating for Abbott with an average price target of …

AbbVie vs. Abbott Laboratories: Which Healthcare Stock Is a Better Buy in 2026?

Choosing between a high-yield pharmaceutical powerhouse and a diversified healthcare leader requires looking at growth and stability. You must decide whether AbbVie (NYSE:ABBV) or Abbott Laboratories (NYSE:ABT) better fits your 2026 investment strategy. AbbVie focuses on high-margin specialized drugs, while Abbott operates across medical …

How Abbott Laboratories (ABT) Affects Rotational Strategy Timing

This article analyzes Abbott Laboratories (ABT) through the lens of rotational strategy timing, utilizing AI models to generate trading strategies. It highlights mixed sentiment, no clear price positioning signal, and compelling upside potential due to the absence of resistance levels above the current price. …

51,393 Shares in Abbott Laboratories $ABT Purchased by St. Louis Financial Planners Asset Management LLC

St. Louis Financial Planners Asset Management LLC recently acquired 51,393 shares of Abbott Laboratories (NYSE:ABT) worth approximately $4.9 million, making it their 10th-largest holding. Institutional investors now own 75.18% of the company, which holds a "Moderate Buy" consensus rating from analysts despite some recent …

What Makes Abbott Laboratories (ABT) a Compelling Investment Opportunity with Reliable Growth

Matrix Asset Advisors, an asset management company, released its Q2 2026 investor letter. A copy of the letter can be downloaded here. The stock market rebounded strongly in the second quarter, with the S&P 500 gaining 15.2% in the quarter and 10.2% year-to-date. Investors …

Abbott (ABT) Stock Trades At A Cash Flow Discount But An Earnings Premium

Abbott Laboratories' stock has dropped 16.4% over the past year, but a Discounted Cash Flow (DCF) analysis suggests a 28.1% upside compared to its current share price, indicating it's undervalued based on future cash flow potential. However, its P/E ratio of 34.6x is higher …

Abbott Stock: Is Wall Street Bullish or Bearish?

Abbott Laboratories HQ photo- by Sundry Photography via iStock Lake County, Illinois-based Abbott Laboratories (ABT) discovers, develops, manufactures, and sells health care products worldwide. The company has a market cap of $182.9 billion and operates through Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and …

Abbott vs Danaher: Which Healthcare Stock Looks Better Positioned Following Earnings?

This article compares Abbott Laboratories (ABT) and Danaher Corporation (DHR) following their recent Q2 2026 earnings reports. Abbott showcased strong performance driven by its diagnostics and medical devices segments, leading to an increased annual profit forecast and positive analyst sentiment. Danaher, while showing core …

Abbott Laboratories stock underperforms Tuesday when compared to competitors

Abbott Laboratories (ABT) stock declined by 1.55% on Tuesday, closing at $105.46. This underperformance occurred on a day when the broader market, including the S&P 500 and Dow Jones Industrial Average, saw significant gains. The stock's fall ended a two-day winning streak for Abbott …

Abbott Laboratories Stock (ABT) Opinions on Q2 Earnings Beat and Guidance Raise

Abbott Laboratories stock rises Monday, still underperforms market

Abbott Laboratories (ABT) stock increased by 1.34% to $107.12 on Monday, marking its second consecutive day of gains. Despite this rise, the stock underperformed the broader market, as the S&P 500 Index rose by 1.48% and the Dow Jones Industrial Average gained 1.32% on …

Abbott Laboratories Lost 16% This Year: One Analyst Sees 35% Gains for the Healthcare Giant

Abbott Laboratories has seen its stock decline by 16% this year, despite five consecutive adjusted EPS beats, primarily due to the financial impact of its $21 billion Exact Sciences acquisition. While the market reacted negatively to GAAP earnings, analysts like Barclays' Matt Miksic see …

Matrix Asset Advisors' Large Cap Value Portfolio adds ABT and MCD; exits NSRGY

* Matrix Asset Advisors' Large Cap Value Portfolio gained in the mid-teens in Q2 2026, roughly in line with the S&P 500, which returned 15.2% and modestly ahead of the Russell 1000 Value Index. * The firm initiated new positions in Abbott Laboratories (NYSE: …

Abbott Laboratories (ABT) Stock Analysis: Navigating a 12% Upside Potential Amid Robust Healthcare Offerings

Abbott Laboratories vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026?

Choosing between Abbott Laboratories (NYSE:ABT) and Eli Lilly (NYSE:LLY) involves weighing the steady diversification of a healthcare conglomerate against the high-velocity expansion of a pharmaceutical leader. Both companies represent different investment profiles. Abbott operates as a diversified healthcare giant with interests ranging from infant …

Abbott (ABT) Stock Looks Like A Bargain Below Fair Value

Abbott Laboratories' stock has dropped 15% over the past year, and a Discounted Cash Flow (DCF) analysis suggests it is undervalued by 28.9%, with an intrinsic value of about $149 per share. However, its P/E ratio of 33.9x is higher than the industry average, …

Abbott Stock And 2 Dividend Compounders Built For Sticky Inflation

This article examines three dividend stocks—Abbott Laboratories (ABT), Consolidated Water (

Abbott Laboratories stock outperforms competitors despite losses on the day

On Thursday, Abbott Laboratories (ABT) shares fell by 2.21% to $105.61, despite a strong trading session for the broader market with both the S&P 500 and Dow Jones Industrial Average rising. This decline ended a six-day winning streak for the stock.

Why Abbott (ABT) Is Up 7.4% After Mixed Q2 Results And Expanded Heart Device, Diagnostics Push

Abbott Laboratories reported mixed Q2 2026 results with increased sales but lower net income and diluted EPS. Despite this, the company's stock rose 7.4% due to strengthening its medical device and diagnostics portfolio, including a significant real-world TriClip heart valve study and expansion in …